*ST天山(300313) - 2023 Q3 - 季度财报(更正)
TIANSHAN BIOTIANSHAN BIO(SZ:300313)2024-07-03 09:05

Financial Performance - The company's revenue for Q3 2023 reached ¥49,233,973.63, representing a 182.78% increase year-over-year[5] - Net profit attributable to shareholders was ¥99,501.92, a 100.61% increase compared to the same period last year[5] - Total operating revenue for the third quarter reached ¥95,556,468.24, a significant increase of 105.6% compared to ¥46,438,688.52 in the same period last year[34] - Total operating costs amounted to ¥107,186,932.20, up 59.5% from ¥67,220,917.63 year-over-year[34] - The net loss for the quarter was ¥12,905,285.94, an improvement from a net loss of ¥28,568,998.45 in the previous year, representing a reduction of 54.8%[35] - The company's gross profit margin decreased to -12.1% from -44.0% year-over-year, indicating improved operational efficiency despite a net loss[34] - Investment income for the quarter was ¥2,462,959.89, a recovery from a loss of ¥8,430,409.24 in the same period last year[35] - The total equity attributable to shareholders of the parent company decreased to ¥71,223,967.16 from ¥84,261,480.39, indicating a decline in retained earnings[35] - The company reported a basic and diluted earnings per share of -0.0417, an improvement from -0.0904 in the same quarter last year[35] Assets and Liabilities - The total assets at the end of the reporting period were ¥318,267,849.41, a decrease of 4.18% from the previous year-end[5] - The company's current assets totaled CNY 108,406,607.62, down from CNY 117,638,304.71 at the start of the year, indicating a decline of approximately 10.5%[30] - The company's total liabilities were CNY 224,954,903.65, slightly down from CNY 225,759,429.69, indicating a marginal decrease of about 0.4%[31] - The total liabilities stood at ¥237,005,183.98, slightly down from ¥237,977,656.18 in the previous quarter[35] - Short-term borrowings decreased to CNY 83,324,712.50 from CNY 94,159,536.10, a reduction of approximately 11.5%[31] Cash Flow - Cash flow from operating activities showed a net outflow of ¥15,921,844.76, a significant decline of 476.87% year-to-date[5] - Operating cash inflow for the period was CNY 89,646,297.27, an increase from CNY 68,572,797.25 in the previous period, representing a growth of approximately 30.7%[36] - Net cash outflow from operating activities was CNY -15,921,844.76, worsening from CNY -2,760,039.21 in the previous period[36] - Cash inflow from financing activities totaled CNY 138,890,000.00, up from CNY 124,480,000.00, indicating an increase of about 11.5%[37] - Cash and cash equivalents decreased to CNY 15,971,162.89 from CNY 47,288,291.92, representing a significant drop of about 66.2%[30] - Cash and cash equivalents at the end of the period decreased to CNY 15,971,162.89 from CNY 70,520,414.30, a decline of approximately 77.6%[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,640[13] - The company reported a total of 40,718,359 shares to be transferred, representing 13.01% of the total shares, as part of a control transfer agreement with China Electric Power Investment New Agricultural Innovation Technology Co., Ltd.[16] - The company’s major shareholder, Huzhou Haohui Enterprise Management Consulting Co., Ltd., holds 69,211,312 shares, accounting for 22.11% of the total share capital, with 15,350,000 shares pledged, which is 4.90% of the total share capital.[19] - The company’s major shareholder, Chen Dehong, has 37,279,083 shares, with 36,509,768 shares pledged, representing 97.94% of his holdings and 11.67% of the total share capital.[20] - The company’s control structure may change to a state of no actual controller if the proposed share transfer is completed.[16] Legal Proceedings - The company has been involved in legal proceedings related to the former actual controller, resulting in the recovery of 37,279,083 shares and 78,345,524 shares from the former shareholders of Elephant Advertising Co., Ltd.[18] - The company is involved in ongoing legal proceedings related to contract fraud, with significant implications for its financial standing and operations[24] - The company received a court ruling to cancel stock held by 30 defendants, which may impact its equity structure and future financial performance[24] Inventory and Accounts Payable - The company's inventory increased by 34.95% to ¥73,100,987.42, attributed to business expansion[10] - The company experienced a 109.99% increase in accounts payable, reaching ¥22,884,212.96, due to business expansion[10] - Accounts receivable increased to CNY 10,860,306.47 from CNY 7,966,972.32, reflecting a growth of approximately 36.5%[30] - Inventory rose to CNY 73,100,987.42 from CNY 54,170,780.11, marking an increase of about 35%[30] Research and Development - Research and development expenses increased to ¥764,036.98, up 111.1% from ¥361,344.55 year-over-year, reflecting the company's commitment to innovation[34] Other Financial Information - The company did not conduct an audit for the third-quarter report[38] - Other comprehensive income after tax amounted to ¥11,980,296.36, contributing positively to the overall financial position despite the net loss[35] - The company reported a cash flow impact from exchange rate changes of CNY 16.97, a significant decrease from CNY 923,060.71 in the previous period[37]